Compare MCB & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCB | RGNX |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.2M | 761.9M |
| IPO Year | 2017 | 2015 |
| Metric | MCB | RGNX |
|---|---|---|
| Price | $91.73 | $11.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $97.50 | $30.38 |
| AVG Volume (30 Days) | 185.2K | ★ 1.0M |
| Earning Date | 01-20-2026 | 03-12-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | ★ 11.64 | N/A |
| EPS | ★ 6.62 | N/A |
| Revenue | ★ $277,514,000.00 | $161,318,000.00 |
| Revenue This Year | $29.07 | $133.58 |
| Revenue Next Year | $7.96 | $45.08 |
| P/E Ratio | $13.90 | ★ N/A |
| Revenue Growth | 2.53 | ★ 91.30 |
| 52 Week Low | $47.08 | $5.04 |
| 52 Week High | $96.75 | $16.19 |
| Indicator | MCB | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 65.29 | 36.41 |
| Support Level | $87.74 | $9.51 |
| Resistance Level | $96.75 | $11.78 |
| Average True Range (ATR) | 3.62 | 1.07 |
| MACD | 0.70 | -0.45 |
| Stochastic Oscillator | 74.08 | 25.30 |
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.